|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | n | Hodgkin | B-cell | T-cell | NOS |
|  |  | n | % | n | % | n | % | n excluded |
| **bio-naïve** | **258** | **21** | **8.1** | **220** | **85.3** | **17** | **6.6** | **30** |
|  ARTIS | 197 | 13 | 6.6 | 174 | 88.3 | 10 | 5.1 | 19 |
|  BSRBR | 30 | 5 | 16.7 | 22 | 73.3  | 3 | 10.0 | 4 |
|  DANBIO | 23 | 2 | 8.7 | 18 | 78.3 | 3 | 13.0 | 4 |
|  RABBIT |  6 | 0 | 0 | 5 | 83.3 | 1 | 16.7 | 1 |
|  Rheuma.pt | 2 | 1 | 50 | 1 | 50 | 0 | 0 | 2 |
| **TNFi** | **202** | **24** | **11.9** | **164** | **81.2** | **14** | **6.9** | **28** |
|  ARTIS | 52 | 6 | 11.5 | 40 | 76.9 | 6 | 11.5 | 7 |
|  BSRBR | 77 | 11 | 14.3  | 63 | 81.8 | 3 | 3.9 | 10 |
|  RATIO | 27 | 5 | 18.5 | 20 | 74.1 | 2 | 7.4 | 0 |
|  DANBIO | 14 | 2 | 14.3 | 10 | 71.4 | 2 | 14.3 | 1 |
|  RABBIT | 12 | 0 | 0 | 11 | 91.7 | 1 | 8.3 | 3 |
|  BIOBADASER | 8 | 0 | 0 | 8 | 100 | 0 | 0 | 0 |
|  GISEA | 6 | 0 | 0 | 6 | 100 | 0 | 0 | 5 |
|  Rheuma.pt | 3 | 0 | 0 | 3 | 100 | 0 | 0 | 2 |
|  ATTRA | 3 | 0 | 0 | 3 | 100 | 0 | 0 | 0 |
| **Rituximab** | **6** | **0** | **0** | **5** | **83.3** | **1** | **16.7** | **0** |
|  ARTIS | 2 | 0 | 0 | 1 | 50 | 1 | 50 | 0 |
|  AIR | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  BSRBR | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  RABBIT | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  BIOBADASER | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
| **Tocilizumab** | **5** | **0** | **0** | **5** | **100** | **0** | **0** | **1** |
|  REGATE | 3 | 0 | 0 | 3 | 100 | 0 | 0 | 0 |
|  DANBIO | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  BIOBADASER | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  GISEA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| **Abatacept** | **3** | **0** | **0** | **3** | **100** | **0** | **0** | **0** |
|  ARTIS | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  ORA | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |
|  GISEA | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 0 |

Supplement Table 1: Lymphoma subtype distribution (Hodgkin, B-cell and T-cell lymphoma) in RA patients in treatment groups in all registers.

NOS: not otherwise specified